Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.
Ito
Akira
A
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan. iakira@cardiol.med.kyshu-u.ac.jp
Fukumoto
Yoshihiro
Y
Shimokawa
Hiroaki
H
D000286:Administration, Sublingual; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017311:Amlodipine / Q000627:therapeutic use; D000788:Angina Pectoris, Variant / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015331:Cohort Studies; D048909:Diabetes Complications; D004095:Dihydropyridines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D005996:Nitroglycerin / Q000627:therapeutic use; D011379:Prognosis; D012907:Smoking / Q000009:adverse effects; D015996:Survival Rate; D014665:Vasodilator Agents / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D014665:Vasodilator Agents; D017311:Amlodipine; C061004:benidipine; D005996:Nitroglycerin